| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/28/2002 | US20020037292 Avian polynucleotide vaccine formula |
| 03/28/2002 | US20020037290 Compositions comprising heat shock proteins or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof |
| 03/28/2002 | US20020037288 As therapeutic agents for T cell tumors or B cell tumors (excluding myeloma) |
| 03/28/2002 | US20020037287 For diagnosis and therapy of myeloma and ovarian cancer |
| 03/28/2002 | US20020037285 For diseases such as rheumatoid arthritis, atherosclerosis, granulomatous diseases and multiple sclerosis |
| 03/28/2002 | US20020037282 Universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
| 03/28/2002 | US20020037250 Polynucleotides and polypeptides which are diagnostic markers for mammary gland cancer. |
| 03/28/2002 | US20020035993 Highly efficient delivery of a large therapeutic mass aerosol |
| 03/28/2002 | DE10135996A1 Identifying metastatic tumor cells and screening for antitumor agents, comprises hybridization to specific cDNA sequences |
| 03/28/2002 | DE10043437A1 Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites Using trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |
| 03/28/2002 | DE10042598A1 Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS The recombinant MVA with the ability to express the HER-2 / neu gene |
| 03/28/2002 | DE10028376A1 Epididymis-spezifische Proteine mit Fibronektin Typ II-Modulen Epididymis-specific proteins with fibronectin type II modules |
| 03/28/2002 | CA2423181A1 Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof |
| 03/28/2002 | CA2423127A1 Immunogen comprising ligand bound hiv envelope protein |
| 03/28/2002 | CA2422911A1 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | CA2422863A1 Use of immidazoquinolinamines as adjuvants in dna vaccination |
| 03/28/2002 | CA2422576A1 Immunomodulatory preparation |
| 03/28/2002 | CA2422568A1 Prognostic indicator |
| 03/28/2002 | CA2422564A1 Influenza a virus haemagglutinin subtype h16 proteins and their encoding nucleic acid |
| 03/28/2002 | CA2422451A1 Haemophilus influenzae basb202 polypeptide, production, vaccine and diagnostic use |
| 03/28/2002 | CA2421576A1 Human polynucleotides and polypeptides encoded thereby |
| 03/28/2002 | CA2420160A1 Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |
| 03/27/2002 | EP1191100A2 Recombinant allergens from the Indianmeal Moth Plodia interpunctella |
| 03/27/2002 | EP1191099A1 Novel polypeptide and dna thereof |
| 03/27/2002 | EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2002 | EP1191035A2 Three members of the cytokin-receptor class II family |
| 03/27/2002 | EP1190257A1 Early detection of flaviviruses using the ns1 glycoprotein |
| 03/27/2002 | EP1190101A1 Compositions and methods for preventing transepithelial transmission of hiv |
| 03/27/2002 | EP1190083A2 Dna constructs based on the eif4a gene promoter |
| 03/27/2002 | EP1190074A1 Recombinant anti-cd40 antibody and uses thereof |
| 03/27/2002 | EP1190065A2 Atp binding cassette transporter protein abc1 polypeptides |
| 03/27/2002 | EP1190061A1 Streptavidin expressed gene fusions and methods of use thereof |
| 03/27/2002 | EP1190057A1 Cloning and expression of a novel 5-ht4 receptor |
| 03/27/2002 | EP1190055A2 Human endogenous retrovirus in breast cancer |
| 03/27/2002 | EP1190050A2 Human transcriptional regulator proteins |
| 03/27/2002 | EP1190048A2 Novel candida albicans genes and proteins coded by said genes |
| 03/27/2002 | EP1189947A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 03/27/2002 | EP1189946A1 ANTI-$g(a) v?$g(b)3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE |
| 03/27/2002 | EP1189917A1 48 human secreted proteins |
| 03/27/2002 | EP1189663A2 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders |
| 03/27/2002 | EP1189641A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/27/2002 | EP1189635A1 Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells |
| 03/27/2002 | EP1189634A1 Treating prostate cancer with anti-erbb2 antibodies |
| 03/27/2002 | EP1189633A2 Method for treating chronic hbv infection |
| 03/27/2002 | EP1189632A1 Pneumococcal surface protein combination vaccine |
| 03/27/2002 | EP1189631A1 Neurodegenerative disorder related gene |
| 03/27/2002 | EP1189628A1 Combination of tumor necrosis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 03/27/2002 | EP1189627A1 Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies |
| 03/27/2002 | EP1189624A1 Hla binding peptides and their uses |
| 03/27/2002 | EP0837673B1 Polymeric lamellar substrate particles for drug delivery |
| 03/27/2002 | EP0831906B1 Treatment of t cell mediated autoimmune disorders |
| 03/27/2002 | EP0712442B1 Vaccine compositions |
| 03/27/2002 | EP0621875B1 Fibrinogen binding protein |
| 03/27/2002 | CN1342202A Soluble receptor BR43X2 and methods for using them for therapy |
| 03/27/2002 | CN1342096A Synergistic tumorcidal response induced by histamine |
| 03/27/2002 | CN1342088A Polypeptide comprising amino acid of AN N-terminal choline binding protein truncate, vaccine derived therefrom and uses thereof |
| 03/27/2002 | CN1342085A Inhibition of differentiation of cytotoxic T-cells by p-selecting ligand (PSGL) antagonists |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1342066A Non-invasive vaccination through skin |
| 03/27/2002 | CN1341595A Nonviscous protein type synthetic compound or its carrier combined compound |
| 03/26/2002 | US6362320 Process for purifying hepatitis B viral surface antigen comprising pres2 peptide |
| 03/26/2002 | US6362319 Glial cell line-derived neurotrophic factor |
| 03/26/2002 | US6362316 Human metabotropic glutamate receptor subtype mGluR6 protein |
| 03/26/2002 | US6362007 For diagnosis and therapy of systemic lupus erythematosus and related diseases, and diseases in which epstein-barr virus has been implicated |
| 03/26/2002 | US6361974 Exonuclease-mediated nucleic acid reassembly in directed evolution |
| 03/26/2002 | US6361970 A polypeptide encoding an isoleucyl trna synthetase; therapy and screening antibiotic compounds |
| 03/26/2002 | US6361946 A bone marrow modulating method in mammals by adminstering a polypeptide that binds to at least one endothelial cell surface receptor to modulates myelopoiesis |
| 03/26/2002 | US6361803 Antioxidant compositions extracted from a wastewater from olive oil production |
| 03/26/2002 | US6361779 Transferrin receptor genes |
| 03/26/2002 | US6361778 Carboxyl terminal of papillomavirus L1 region is not required for formation of virus-like particles |
| 03/26/2002 | US6361777 Method of coupling polysaccharides to proteins |
| 03/26/2002 | US6361776 Polypeptide isolated from mycobacterium vaccae comprising specified amino acid sequence, capable of eliciting and/or enhancing immune response to heterologous antigen |
| 03/26/2002 | US6361775 Compositions and methods for vaccines comprising α-galactosyl epitopes |
| 03/26/2002 | US6361770 Introducing ex vivo nucleic acid molecule comprising sequence encoding tap-1 into tumor cell, expressing tap-1 in tumor cell, permitting recognition of tumor by mammal's immune response, introducing tumor cell into mammal |
| 03/26/2002 | CA2137551C A novel endothelial cell molecule mediating lymphocyte binding in man |
| 03/26/2002 | CA1341351C Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| 03/21/2002 | WO2002023184A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | WO2002022885A1 Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
| 03/21/2002 | WO2002022851A2 Novel tumor-associated marker |
| 03/21/2002 | WO2002022825A2 The c. albicans tec1 gene (catec1) and the coded tec1p protein |
| 03/21/2002 | WO2002022819A2 Calcium binding proteins |
| 03/21/2002 | WO2002022807A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022795A2 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | WO2002022783A2 Liver gene expression associated with the inhibition of hbv replication or transcription |
| 03/21/2002 | WO2002022782A2 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 03/21/2002 | WO2002022687A2 Viral chemokine-tumur antigen fusion proteins |
| 03/21/2002 | WO2002022685A2 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022680A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 03/21/2002 | WO2002022679A2 Variants of phleum pratense allergenic proteins |
| 03/21/2002 | WO2002022674A2 VARIANTS OF THE MAJOR ALLERGEN Par j 2 OF Parietaria judaica |
| 03/21/2002 | WO2002022664A2 Antigenic proteins of shrimp white spot syndrome virus and uses thereof |
| 03/21/2002 | WO2002022659A2 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 03/21/2002 | WO2002022648A2 Compositions and methods for inducing specific cytolytic t cell responses |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022169A2 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS |
| 03/21/2002 | WO2002022168A2 Vaccine against streptococcus pneumoniae |
| 03/21/2002 | WO2002022167A2 Vaccine against streptococcus penumoniae |